Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03352726 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut Allergic Subjects
A Phase 1 study, sponsored by DBV Technologies.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT03352726 is a Phase 1 study that has completed, run by DBV Technologies. The registered enrollment target is 27 participants.
The verdict
NCT03352726, a Phase 1 study, has completed, sponsored by DBV Technologies.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The study aims to assess the biological potency of the In-House Reference Preparation (IHRP) of peanut allergens extract by a quantitative Skin Prick Test (SPT) method in peanut-allergic subjects.
Interventions
- DRUG DBV712 IHRP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2017-11-24 |
| Est. Completion | 2018-06-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03352726
The ClinicalTrials.gov registry entry for NCT03352726 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is DBV Technologies, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DBV712 IHRP is the first listed.
NCT03352726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03352726 about?
NCT03352726 is a clinical study titled "A Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut Allergic Subjects". The study aims to assess the biological potency of the In-House Reference Preparation (IHRP) of peanut allergens extract by a quantitative Skin Prick Test (SPT) method in peanut-allergic subjects.
What is the current status of trial NCT03352726?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2017-11-24. Estimated completion is 2018-06-29.
What interventions are being tested in trial NCT03352726?
The interventions under investigation include: DBV712 IHRP (DRUG).
Who is sponsoring clinical trial NCT03352726?
This trial is sponsored by DBV Technologies, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.